Respiratory infections are a major cause of morbidity and mortality in persons living in tropical and developing countries. Although the number and variety of pulmonary pathogens found in tropical areas are enormous, most infections are due to routine viral, bacterial, and mycobacterial organisms. Infection with Mycobacterium tuberculosis is particularly common. The World Health Organisation (WHO) estimates that 8-10 million new cases of tuberculosis occur each year worldwide, and over three quarters of these cases are in the tropics. ' Infection with the human immunodeficiency virus (HIV) is also common in many tropical countries. In 1992 the WHO estimated that 9-11 million adults, mostly in developing countries, were infected with HIV.2 Although AIDS is basically the same disease in all parts of the world, the prevalence of microorganisms in an environment governs the patterns of disease encountered. Thus, substantial variation occurs in the combination of diseases that predominate in different areas of the world.3 Even within a given country, diseases vary depending on whether the population is urban or rural.
The overlap of HIV infection and the many pulmonary pathogens found in the tropics has made pulmonary infections a common manifestation of HIV infection. In a large study from Nairobi, Kenya pulmonary disorders accounted for 28-4% of admissions in HIV-1 seropositive patients compared with 16-5% in seronegative patients. 4 Although the spectrum of disease can be quite broad, most of the pulmonary infections in HIV-1 infected patients are similar to those seen in non-HIV infected individuals. The geographical differences are primarily due to varying frequencies rather than the kinds of infections.5 In the USA Pneumocystis carinii pneumonia and bacterial pneumonia are the most common infectious pulmonary complications of HIV infection.6 Tuberculosis, though increasing in the USA, is still much less common. On the other hand, in tropical countries where infection with M tuberculosis is highly prevalent, tuberculosis and bacterial pneumonia represent the major pulmonary infections (table 1) . In a recent study from Burundi, 302 consecutive patients hospitalised for acute respiratory disease were evaluated with fibreoptic bronchoscopy.7 Of the total, an astonishing 222 patients (73 5%) were HIV-1 seropositive. Tuberculosis and bacterial pneumonias were the most common pulmonary infections and occurred in approximately equal frequency in the HIV-1 seropositive and seronegative groups. Unlike in the USA, P carinii pneumonia occurred in only 11 (5%) HIV-1 seropositive patients.
Of all the pulmonary infections encountered in the tropics clearly M tuberculosis is one of the most significant pathogens. Data from subSaharan Africa and Haiti have shown that between 17% and 66% of tuberculosis cases are HIV-1 seropositive.2 Moreover, studies of the pulmonary complications of HIV infection in Africa have noted that 50% of seropositive patients presenting with pulmonary symptoms have tuberculosis. 7 The significant impact of HIV on tuberculosis in developing countries will be discussed by Nunn and colleagues in another article in this series. This review will focus on the non-tuberculous pathogens affecting HIV Although nocardiosis is frequently disseminated at presentation, the lung is the most common site of involvement.20 Symptoms of nocardiosis in HIV-1 infected patients are usually non-specific: most patients present with fever, night sweats, malaise, cough, and weight loss. The chest radiograph is frequently notable for upper lobe, cavitary infiltrates24 and is thus indistinguishable from tuberculo-S1S.
Definitive diagnosis requires culture of respiratory specimens because blood cultures are rarely positive.20 Since cultures are unlikely to be available in many areas, the diagnosis should be suspected if the characteristic morphology is seen on Gram stain; filamentous, beaded, branching Gram positive rods. In a review by Javaly and colleagues20 the Gram stain was suggestive of nocardial infection in 47% of patients. The organism may also stain weakly acid fast. The radiographic presentation, coupled with the fact that the organism can stain acid fast, may cause the disease to be misdiagnosed as tuberculosis. In fact, two such cases were reported from Uganda. 25 The optimum regimen and duration of therapy for nocardiosis in the setting of HIV-1 infection are not known. Sulphonamides (trimethoprim-sulphamethoxazole) have been the treatment of choice in non-HIV-1 infected patients with nocardiosis.20 It is likely that these agents will also be effective in HIV-1 infected patients although the high rate of toxicity to trimethoprim-sulphamethoxazole26 may limit its use in this population. Other agents with in vitro activity to N asteroides include minocycline, some third generation cephalosporins, amikacin, and amoxacillinclavulanic acid.20 Some authors recommend treatment for at least 6-12 months and, perhaps, indefinitely since recurrences have been reported.
MELIOIDOSIS
Meliodosis is an infection caused by the Gram negative motile bacillus, Pseudomonas pseudomallei. The disease is endemic in south east Asia, northern Australia, and West Africa. Amphotericin B is the current treatment of choice and the recommended duration of treatment is 6-8 weeks for a total cumulative dose of 40 mg/kg. However, in the study cited above48 nine patients were treated with 400 mg itraconazole for eight weeks and six responded well. Six of eight patients treated with amphotericin also responded well. Four patients died before treatment was begun. As with melioidosis, this infection may become more common as HIV moves into rural areas.
Pneumocystis pneumonia (PCP)
The taxonomy of Pneumocystis carinii is currently in question. Long considered a protozoa, recent data have shown that the organism is more closely related to fungi.50 Nevertheless P carinii is a ubiquitous organism found in every region of the world5' and it is the most common infectious pulmonary complication of HIV infection in the USA: PCP develops in 75% of HIV infected patients at some time during the course of their disease.6
The frequency of PCP is, however, quite different in tropical countries. In a review of the literature Blaser and Cohn examined the reported frequencies of various HIV related complications and the way in which they differed from region to region and population to population.52 The frequency of PCP (20%) reported among persons native to the tropics was significantly lower than for persons who had acquired HIV infection through blood borne or sexually transmitted routes in more developed countries. PCP was diagnosed more frequently in developed countries among natives of developed countries (73%) than among natives of the tropics (35%).
The first cases of PCP noted in African patients with AIDS were diagnosed in Europe.5' Five of 23 AIDS patients reported by Clumeck and colleagues had PCP, three of whom were diagnosed at post mortem examination. PCP has been identified in 14-24% of African patients with AIDS treated in Europe and in 37% of patients with AIDS of African origin in the USA.5 Whether the exposure to P carinii occurred in Africa or after leaving is not known. were HIV-2 positive, and 14% reacted to both viruses. A total of 100 patients (21%) died. The pathology of 78 necropsies showed, not surprisingly, that the predominant cause of death in the HIV seropositive patients (40%) was disseminated tuberculosis. Pyogenic or bronchopneumonias were the second leading cause of death. PCP was found in only 9% of the HIV infected patients who underwent necropsy. It was also identified in another patient who died of nocardiosis, providing an overall prevalence of 12%. PCP was not found in a limited post mortem series of 22 Since most patients in tropical and developing countries will have bacterial pneumonia or tuberculosis, the diagnostic evaluation should focus on these pathogens. As noted in the figure all patients should be evaluated for acid fast bacilli in their sputum. For patients with a clinical and radiographical presentation consistent with bacterial pneumonia, penicillin should be started. If the sputum is smear negative for acid fast bacilli, and the patient is unlikely to have bacterial pneumonia or tuberculosis on clinical grounds, bronchoscopy should be considered to rule out opportunistic infections. Where these facilities are not available, patients should be treated empirically for tuberculosis. In areas where PCP has been documented to occur, empirical treatment with trimethoprim-sulphamethoxazole should also be considered. Although not widely available, the use of sputum induction could be helpful in patients who are not producing sputum spontaneously.
As noted above, since most pleural effusions in HIV infected patients are caused by tuberculosis, pleural fluid and sputum should be examined for the presence of acid fast bacilli. Unless a bacterial empyema is discovered, treatment for tuberculosis should be begun until cultures have returned or the patient has shown clinical improvement.
Because of the lack of diagnostic facilities in many areas of the developing world, more unusual pathogens may be difficult to diagnose. Fortunately, due to the rarity of these infections, sophisticated facilities are seldom needed. For now, physicians caring for HIV infected patients in the tropics or returning from the tropics should be familiar with the more comon manifestations of the pulmonary complications of HIV infection. Tuberculosis and bacterial pneumonias are clearly the most frequently encountered pulmonary diseases. However, as the HIV epidemic moves into rural areas the spectrum of disease is likely to change, with some of the more unusual pathogens -for example, melioidosis, Penicillium sp -becoming more common. Continued surveillance is therefore necessary so that diagnostic and treatment algorithms can be modified as necessary. 
